Table 1 Performance of individual and combination host gene methylation markers in discriminating CIN3 + for self-collected cervicovaginal swabs by Area under the curve, sensitivity and specificity

SOX17

304

0.615

0.543–0.687

de Waard, 2024

C13ORF18

304

0.587

0.514–0.659

de Waard, 2023

has-miR124-2

304

0.618

0.551–0.686

de Waard, 2024

ITGA4

304

0.622

0.550–0.695

de Waard, 2024

DLX1

304

0.625

0.553–0.697

de Waard, 2024

JAM3

304

0.635

0.565–0.705

de Waard, 2023

GHSR

304

0.645

0.576–0.714

de Waard, 2023

ANKRD18PC

304

0.646

0.575–0.718

de Waard, 2023

ASTN1

304

0.654

0.583–0.726

de Waard, 2024

RXPF3

304

0.67

0.599–0.741

de Waard, 2024

ST6GALNAC5

304

0.676

0.609–0.743

de Waard, 2023

PAX1

304

0.676

0.605–0.746

de Waard, 2023

SST

304

0.7

0.637–0.764

de Waard, 2023

EPB41L3

304

0.72

0.655–0.790

de Waard, 2023

ZNF671

304

0.761

0.695–0.826

de Waard, 2024

ZNF582

304

0.731

0.665–0.798

de Waard, 2023

POU4F3

304

0.745

0.682–0.808

de Waard, 2023

SOX1

304

0.746

0.680–0.812

de Waard, 2023

ZSCAN1

304

0.762

0.701–0.823

de Waard, 2023

LHX8

304

0.781

0.721–0.841

de Waard, 2023

ZIC1

304

0.787

0.729–0.844

de Waard, 2023

ASCL1

304

0.806

0.749–0.863

de Waard, 2023

ITGA4/ASCL1/FAM19A4

304

0.83

de Waard, 2024

ANKRD18CP/LHX8/EPB41L3

304

0.84

de Waard, 2023

Marker

Pop

n=

Sens.

95% CI

Spec.

95% CI

Study

GynTect

Referral

68

31.6%

15–54%

95.9%

85–99%

Klischke, 2021

ASCL1

Screening

593

51.2%

40.6–61.7%

80.5%

77.0-83.9%

Verhoef, 2023

GynTect

Screening

304

59.0%

91.0%

de Waard, 2024

QIAsure

Screening

304

65.0%

72.0%

de Waard, 2024

LHX8

Screening

593

65.1%

55.0-75.2%

69.2%

65.2–73.2%

Verhoef, 2023

ASCL1/LHX8

Screening

593

73.3%

63.9–82.6%

61.1%

56.9–65.4%

Verhoef, 2023

ANKRD18CP/LHX8/

EPB41L3

Screening

304

82.0%

74.0%

de Waard, 2024

ITGA4/ASCL1/FAM19A4

Screening

304

84.0%

70.0%

de Waard, 2024